Intervention not reported
Vessel patency at 30 days · patients seeking treatment for initial management of acute limb ischaemia
It is very uncertain whether the intervention changes vessel patency at 30 days (very low certainty).
1 finding from 1 review
Intervention not reported
Major haemorrhage at 30 days · patients seeking treatment for initial management of acute limb ischaemia
The intervention may leads to higher major haemorrhage at 30 days (low certainty).
1 finding from 1 review
Intervention not reported
Stroke at 30 days · patients seeking treatment for initial management of acute limb ischaemia
The intervention showed no clear difference in stroke at 30 days (low certainty).
1 finding from 1 review
Intervention not reported
Distal embolisation at 30 days · patients seeking treatment for initial management of acute limb ischaemia
It is very uncertain whether the intervention changes distal embolisation at 30 days (very low certainty).
1 finding from 1 review
Ease and frequency of use Frequency of use (0 = never to 4 = several times a day) · adults with low vision
1 finding from 1 review
Intervention not reported
Maternal length of hospital stay (days) · pregnant women and their infants
The intervention showed no clear difference in maternal length of hospital stay (days) (low certainty).
1 finding from 1 review
Intervention not reported
Infant length of hospital stay (days) · pregnant women and their infants
The intervention showed no clear difference in infant length of hospital stay (days) (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life: Days of work lost per crisis · adults and children with sickle cell disease
The intervention showed no clear difference in quality of life: Days of work lost per crisis (moderate certainty).
1 finding from 1 review
All‐cause mortality (within 30‐days after surgery: any reported death) · adults undergoing non‐cardiac surgery
1 finding from 1 review
Acute stroke (within 30‐days after surgery: new focal neurologic deficit with signs and symptoms lasting longer than 24 hours) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists may leads to lower acute stroke (within 30‐days after surgery: new focal neurologic… compared with control (low certainty).
1 finding from 1 review
Cardiac mortality · adults undergoing non‐cardiac surgery
1 finding from 1 review
Myocardial infarction (within 30‐days after surgery: as detected on an electrocardiogram or trans‐oesophageal echocardiogram) · adults undergoing non‐cardiac surgery
1 finding from 1 review
Acute stroke (within 30‐days after surgery: new focal neurologic deficit with signs and symptoms lasting longer than 24 hours) · adults undergoing non‐cardiac surgery
1 finding from 1 review
All‐cause mortality (within 30‐days after surgery: any reported death) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists showed no clear difference in all‐cause mortality (within 30‐days after surgery: any reported death) compared with control (moderate certainty).
1 finding from 1 review
Cardiac mortality · adults undergoing cardiac surgery
1 finding from 1 review
Myocardial infarction (within 30‐days after surgery: sudden death or death resulting from a primarily identifiable cardiac cause) · adults undergoing cardiac surgery
Alpha‐2 adrenergic agonists showed no clear difference in myocardial infarction (within 30‐days after surgery: sudden death or… compared with control (moderate certainty).
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption
1 finding from 1 review
Frequency of drinking (no. days drinking/week) at 12 months · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review
Drinking Intensity · people with hazardous or harmful alcohol consumption as identified by a screening tool
1 finding from 1 review